ARCHIVES

AZURE Trial: Zoledronic Acid Didn’t Improve DFS In Stage II/III

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

In Brief: Cox Leaving Columbia To Be Physician In Chief At M.D. Anderson; Will Continue to Head RTOG

April 15, 1988

FDA, ASCO Meet to Review Drug Approval Endpoints

April 25, 2003

Project Enlists PC Users In Quest For Cancer Drugs.

April 6, 2001

Knowing Tumor Cell Structure Improves Treatment Decisions

March 27, 2009

ONS To Fund 21 Grants In ’94 Deadline Dec. 1

June 11, 1993

In Brief: Whittaker Corp, Trying To Hire NCI Director; Environmental Carcinogenesis On NCAB Agenda

February 13, 1976